SLU‑PP‑332
Experimental “exercise-mimetic” compound that improved endurance in mice; not studied in humans, so unproven.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
SLU-PP-332 vs SLU-PP-915DETAILED OVERVIEW
What is SLU-PP-332?
SLU-PP-332 is an experimental compound that the press calls an “exercise mimetic”. It has not been approved as a medicine anywhere; it is sold on the black market as a research chemical, and its purity and contents may be unreliable.
In mice, the number of mitochondria (the cell’s energy-producing parts) in the muscles increased, and endurance improved by about 50%. The compound switches on a protein that directs the cells’ energy production. It has not been studied in humans, so its effect and its safety are both unknown. The label “exercise mimetic” does not mean that it replaces exercise. In theory it could also help tumors grow, because the pathway it switches on is linked to poor outcomes in several tumor types. Its effects on the heart, liver and kidneys are unknown. There is no safety data for pregnancy or breastfeeding. It counts as banned in competitive sport.
Mechanism
ERRα (Estrogen-related receptor alpha) synthetic agonist; upregulates PGC-1α + mitochondrial biogenesis
Half-life
About 6-8 hours, estimated from mice; no human data
Onset time
Mitochondrial-biogenesis marker 2-4 weeks in mice; not documented in humans
Legal status
Research-only – NOT an FDA / EMA Rx, no active Phase 1 human trial as of January 2026. WADA NOT explicitly listed; S0 catch-all + monitoring concern applies.
Community interest in SLU-PP-332 comes from its "exercise-mimetic" framing: reports describe tangible fat-loss and insulin-sensitivity benefits, attributed to enhanced mitochondrial respiration and ERR-driven transcription – the layer that produces the endurance/exercise-like effects. A consistently repeated caveat is poor oral absorption: injectable, gel or powder routes reportedly raise levels far more effectively than oral dosing.
Reports frequently stack it with Cardarine or injectable L-carnitine, as the pathways are considered complementary (AMPK vs ERR). It is explicitly not viewed as a "magic exercise pill", and the field has already moved toward a successor molecule (SLU-PP-915) promising better bioavailability – a reminder of how experimental this compound still is.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Billon C, Sitaula S, Banerjee S et al. . Synthetic ERRα agonist SLU-PP-332 enhances exercise-induced metabolic adaptations in mice. bioRxiv preprint 2024 (Salk Institute, peer-review pending).
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J, Hayes ME, Xu W, Hamilton A, Newman JD, Downes M, Evans RM, Burris TP . Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.. ACS Chem Biol.
Fan W, Oh TG, Wang HJ, Yu RT, Atkins AR, Downes M, Evans RM . Estrogen-related receptors regulate innate and adaptive muscle mitochondrial energetics through cooperative and distinct actions.. Proc Natl Acad Sci U S A.
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP . A Synthetic ERR Agonist Alleviates Metabolic Syndrome.. J Pharmacol Exp Ther.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Unknown human side-effect profile: no Phase 1 or any human clinical trial exists, so human toxicity, the side-effect spectrum and tolerability are entirely uncharacterized (preclinical mouse data only, Billon 2024 preprint).
- Potential proliferative/oncologic risk: sustained ERRα activation is a signaling pathway associated with proliferation and poor prognosis in several cancers (breast, prostate); a theoretical tumor-promoting risk of chronic agonism cannot be excluded in the absence of human data (Audet-Walsh 2015, PMID 25587719).
- Possible cardiac effects: ERRα is a central regulator of myocardial mitochondrial bioenergetics; the impact of pharmacologic agonism on cardiac energetics is undocumented in humans, and cardiotoxicity or arrhythmia cannot be excluded.
- Unknown hepatic and renal burden: although the mouse trial reported no ALT/AST elevation over 6 weeks (Billon 2024 preliminary), there is no human hepato- or nephrotoxicity data, and the safety of chronic oral dosing is uncharacterized.
- Hazards of black-market (UGL) sourcing: no legitimate pharmaceutical source exists; the 2024-2025 research-chemical supply carries risks of counterfeiting, under-tested purity, contamination and degradation (the COA is often missing or fabricated).
- Non-validated dosing: the 50 mg/kg/day mouse dose cannot be extrapolated directly to a human dose (due to body-surface-area correction and species differences), so the risk of overdose and the therapeutic window are entirely unknown.
Contraindications · 6
- Any human use outside a clinical trial: as of January 2026 there is no approved indication and no active Phase 1 trial, so no legitimate human use exists and self-experimentation is not advised.
- Active or prior malignancy, or hormone-sensitive cancer: ERRα agonism activates a proliferative signaling pathway, which is theoretically contraindicated in an oncologic context (Audet-Walsh 2015, PMID 25587719).
- Pregnancy and breastfeeding: there is no reproductive toxicity or teratogenicity data, the risk of fetal/infant exposure is unknown, and it should therefore be avoided.
- Children and adolescents: there is no Phase 1 indication and the effect on a developing organism is entirely uncharacterized, so it must not be used.
- Pre-existing cardiovascular disease: ERRα regulates myocardial mitochondrial energetics, the cardiac impact of pharmacologic agonism is undocumented in humans, and it should therefore be avoided in heart disease.
- Competitive athletes (WADA): although SLU-PP-332 is not explicitly listed, the S0 'non-approved substance' catch-all clause prohibits any pre-Phase 2 research chemical, so it is de facto WADA-banned and should be avoided in competition.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Synthetic ERRα agonist SLU-PP-332 enhances exercise-induced metabolic adaptations in mice
Billon C, Sitaula S, Banerjee S et al.
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J, Hayes ME, Xu W, Hamilton A, Newman JD, Downes M, Evans RM, Burris TP
Estrogen-related receptors regulate innate and adaptive muscle mitochondrial energetics through cooperative and distinct actions.
Fan W, Oh TG, Wang HJ, Yu RT, Atkins AR, Downes M, Evans RM
A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP
Telegram
Have a question about SLU‑PP‑332?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
